Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3
Key Highlights
- ➤Zymeworks (ZYME) gets $55 million upfront from Roche for exclusive global ZW209 license
- ➤Zymeworks can receive $40 million upon Phase 1b initiation
- ➤Agreement includes up to $718 million in additional development, commercial and sales milestones
- ➤Zymeworks eligible for tiered high-single-digit to mid-teen royalties on global net sales
- ➤Roche funds Phase 1a and assumes subsequent global development and commercialization responsibilities
Expert Statements
Adam Schayowitz, Executive Vice President and Head of R&D at Zymeworks
“This collaboration allows us to continue advancing ZW209 through its initial clinical development while leveraging Roche’s complementary capabilities to accelerate and expand its development across indications and treatment settings. The agreement also reflects our broader strategy of generating innovative programs through our R&D engine and partnering selected assets in ways that share development risk while preserving meaningful participation in their future success”
Boris L. Zaïtra, Head of Corporate Business Development at Roche
“ZW209 represents an innovative approach that complements our ongoing efforts to develop new treatment options for people living with lung cancer”
Boris L. Zaïtra, Head of Corporate Business Development at Roche
“We look forward to collaborating with Zymeworks to fully explore its therapeutic potential”
* Zymeworks to receive a $55 million upfront payment and a $40 million payment upon initiation of the Phase 1b trial, with potential for up to $718 million in additional development, commercial and sales-based milestones * Zymeworks also eligible to receive tiered high-single-digit to mid-teen royalties on global net sales protected by patents extending into 2040’s * Zymeworks will conduct the Phase 1a monotherapy clinical trial of ZW209 in collaboration with Roche * U.S. FDA IND clearance received with additional global regulatory applications planned to support the opening of clinical study sites outside the U.S. * Transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 * Conference call with Zymeworks management on October 27 at 8:30 am Eastern Time (ET) VANCOUVER, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that it has entered into a global license and collaboration agreement with Roche for the research, development and commercialization of ZW209, a T cell engager targeting DLL3.
Get started
Create a free account to read the full story.